 |
 |
   |
Development Approach
Reapplication of Known CompoundsA final component of MacuSight's unique comprehensive drug development approach is the reapplication to the eye of known compounds that possess proven safety and efficacy profiles. This approach, which significantly mitigates many of the major risks associated with drug development, allows the company to expedite its product development timelines and increase the likelihood of clinical success. MacuSight's work with its lead sirolimus-based product candidate clearly illustrates the company's approach to reapplication. The company has strategically selected a compelling known compound (sirolimus) and is optimizing its administration for the treatment of various ocular diseases and conditions. This compound is particularly attractive to MacuSight based on the fact that it has been safely administered to humans for several years and has demonstrated efficacy in other therapeutic applications (prevention of organ transplant rejection and maintaining the opening of treated arteries in patients with coronary artery disease). Based on sirolimus' proven safety and efficacy, MacuSight believes that its product candidate has a clear and low-risk development path. |
  "This approach allows the company to expedite its product development timelines and increase the likelihood of clinical success." |